All In Biotech

Drug Trial Radar · NCT01014988

Safety Study to Assess IV Zanamivir for Treatment of Influenza Infection in Patients Who Are in Hospital

An Open-label, Multi-center, Single Arm Study to Evaluate the Safety and Tolerability of Intravenous Zanamivir in the Treatment of Hospitalized Adult, Adolescent and Pediatric Subjects With Confirmed Influenza Infection

Last checked: Nov 20, 2026Latest source record: Mar 28, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

202

Actual

Start

Nov 2009

Primary completion

Feb 2015

Study completion Feb 2015

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Nov 17, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 6 months
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine whether zanamivir aqueous solution given by intravenous injection is safe in treating hospitalized patients with confirmed influenza infection. A single arm open-label design has been selected to achieve the primary objective of providing regulatory authorities with safety data on IV zanamivir.

Conditions

  • Influenza, Human

Interventions

  • zanamivir aqueous solutionDrug

    Zanamivir aqueous solution 10mg/mL is a clear, colorless, single use, sterile non-preserved preparation containing 10mg of zanamivir in each milliliter, and made isotonic with sodium chloride. It is presented in 20mL clear glass vials closed with rubber stoppers. Each vial contains 200mg of zanamivir.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Any Adverse Event (AE) Considered to be Related to Study TreatmentTime frame: Up to post-treatment (PT) + 23 days
  2. Number of Participants With Any Severe or Grade 3/4 AEsTime frame: Up to post-treatment (PT) + 23 days
  3. Number of Participants With Any Severe or Grade 3/4 Treatment-related AETime frame: Up to post-treatment (PT) + 23 days
  4. Number of Participants Who Permanently Discontinued the Study Treatment Due to an AETime frame: Up to 10 days
  5. Number of Participants Who Were Permanently Discontinued From the Study Due to an AETime frame: Up to post-treatment (PT) + 23 days
  6. Number of Participants With the Indicated Clinical Chemistry Values Relative to the Normal Range at Baseline (Day 1) and Day 5Time frame: Baseline (Day 1) and Day 5
  7. Number of Participants With the Indicated Hematology Values Relative to the Normal Range at Baseline (Day 1) and Day 5Time frame: Baseline (Day 1) and Day 5
  8. Number of Participants With the Indicated Treatment-emergent (TE) Grade 3/4 Clinical Chemistry ToxicitiesTime frame: Up to post-treatment (PT) + 23 days
  9. Number of Participants With the Indicated Treatment-emergent (TE) Grade 3/4 Hematology ToxicitiesTime frame: Up to post-treatment (PT) + 23 days
  10. Median Heart Rate at Baseline (Day 1) and Day 5Time frame: Baseline (Day 1) and Day 5
  11. Median Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at Baseline (Day 1) and Day 5Time frame: Baseline (Day 1) and Day 5
  12. Median Oxygen Saturation Measured Via Transcutaneous Oximetry (TCPO2) at Baseline (Day 1) and Day 5Time frame: Baseline (Day 1) and Day 5
  13. Median Respiration Rate at Baseline (Day 1) and Day 5Time frame: Baseline (Day 1) and Day 5
  14. Median Body Temperature at Baseline (Day 1) and Day 5Time frame: Baseline (Day 1) and Day 5
  15. Number of Participants Assessed as Normal/Abnormal (Clinically Significant [CS] and Not Clinically Significant [NCS]) for 12-lead Electrocardiogram (ECG) at Baseline (Day 1)Time frame: Baseline (Day 1)
  16. Median Corrected QT Interval (QTc) for Heart Rate by Fridericia's Formula (QTcF) and Bazett's Formula (QTcB) at Baseline (Day 1) and Day 5Time frame: Baseline (Day 1) and Day 5

Locations

110 sites in 13 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Birmingham, Alabama

  • GSK Investigational Site

    Phoenix, Arizona

  • GSK Investigational Site

    Little Rock, Arkansas

  • GSK Investigational Site

    San Diego, California

  • GSK Investigational Site

    Stamford, Connecticut

  • GSK Investigational Site

    Washington D.C., District of Columbia

  • GSK Investigational Site

    Washington D.C., District of Columbia

  • GSK Investigational Site

    Gainesville, Florida

  • GSK Investigational Site

    Tampa, Florida

  • GSK Investigational Site

    Atlanta, Georgia

  • GSK Investigational Site

    Decatur, Georgia

  • GSK Investigational Site

    Indianapolis, Indiana

  • GSK Investigational Site

    Topeka, Kansas

  • GSK Investigational Site

    Louisville, Kentucky

  • GSK Investigational Site

    New Orleans, Louisiana

  • GSK Investigational Site

    Boston, Massachusetts

  • GSK Investigational Site

    Boston, Massachusetts

  • GSK Investigational Site

    Saint Paul, Minnesota

  • GSK Investigational Site

    Kansas City, Missouri

  • GSK Investigational Site

    St Louis, Missouri

  • GSK Investigational Site

    Butte, Montana

  • GSK Investigational Site

    Camden, New Jersey

  • GSK Investigational Site

    New Hyde Park, New York

  • GSK Investigational Site

    Chapel Hill, North Carolina

  • GSK Investigational Site

    Charlotte, North Carolina

  • GSK Investigational Site

    Cleveland, Ohio

  • GSK Investigational Site

    Columbus, Ohio

  • GSK Investigational Site

    Toledo, Ohio

  • GSK Investigational Site

    Portland, Oregon

  • GSK Investigational Site

    Philadelphia, Pennsylvania

  • GSK Investigational Site

    Pittsburgh, Pennsylvania

  • GSK Investigational Site

    Memphis, Tennessee

  • GSK Investigational Site

    Memphis, Tennessee

  • GSK Investigational Site

    Dallas, Texas

  • GSK Investigational Site

    Dallas, Texas

  • GSK Investigational Site

    Fort Worth, Texas

  • GSK Investigational Site

    Houston, Texas

  • GSK Investigational Site

    Salt Lake City, Utah

  • GSK Investigational Site

    Richmond, Virginia

  • GSK Investigational Site

    Milwaukee, Wisconsin

Showing 40 of 110 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.